<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094675</url>
  </required_header>
  <id_info>
    <org_study_id>2018H0179</org_study_id>
    <nct_id>NCT04094675</nct_id>
  </id_info>
  <brief_title>Sirolimus for Cowden Syndrome With Colon Polyposis</brief_title>
  <official_title>Sirolimus for Cowden Syndrome With Colon Polyposis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PTEN Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colon polyposis (the presence of multiple colon polyps) is very common with Cowden syndrome,
      as over 60% of patients have 50 or more polyps. In a previous clinical trial, some
      participants had reduction in the number of colon polyps with the use of the medication
      sirolimus for a very short time period. This study is investigating sirolimus and its effect
      on the number of colon polyps in patients with Cowden syndrome and polyposis over a 1 year
      period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PTEN is a tumor suppressor gene that regulates the cell cycle through the phosphoinositide
      3-kinase (PI3K)/Akt/mTOR pathway. When germline mutations in PTEN occur, the result is Cowden
      syndrome (or less commonly one of several related disorders collectively called the PTEN
      hamartoma tumor syndrome). This is characterized by the growth of hamartomas and a high risk
      of cancer in multiple organ systems. This includes colon polyps in 92.5% of Cowden syndrome
      patients and 64% with an estimated 50 or more polyps. Although outcomes of this are under
      reported, series suggest 20-38% of patients will receive colectomy.

      Current clinical practice for Cowden syndrome is based on close surveillance for the
      development of cancers. Sirolimus (also known as rapamycin) is a specific inhibitor of mTOR
      that is FDA-approved for immunosuppression and use in several types of cancers as
      chemotherapy. It has also been used successfully in other hamartomatous syndromes including
      lymphangioleiomyomatosis. There is also a completed pilot clinical trial for adults with
      Cowden syndrome in which some had reduction in the number of colon polyps with the use of the
      medication sirolimus for a very short time period.

      This will be an open-label pilot trial to determine whether sirolimus reduces colon polyp
      burden in Cowden syndrome. Sirolimus will be administered for one year. Colonoscopy with
      polyp estimation will be performed at trial entrance and at study completion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label pilot trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in colon polyp burden by number</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of change in number of colon polyps. This will be assessed for each segment of colon (ascending, transverse, descending, sigmoid, rectum) and then aggregated into a total number of colon polyps. The entrance result will be compared to the final result for each participant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in colon polyp burden by staging</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of change in staging of colon polyps by using the International Society for Gastrointestinal Hereditary Tumors (InSIGHT) polyposis staging system. The InSight staging system divides colorectal polyposis into 5 progressive stages based on polyp number and size (Stage 0: &lt;20 polyps, all &lt;5 mm; Stage 1: 20-200 polyps, most &lt;5 mm, none, &gt;1 cm; Stage 2: 200-500 polyps, &lt;10 that are &gt;1 cm; Stage 3: 500-1000 polyps or any number if there are 10-50 that are &gt;1 cm and amenable to complete polypectomy; Stage 4: &gt;1000 polyps and/or any polyps grown to confluence and not amenable to simple polypectomy; any high-grade dysplasia or invasive cancer). The entrance result will be compared to the final result for each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in well-being assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment in change in overall health and quality of life as quantified by the SF-36 (Short Form) Health Survey. The SF-36 is a widely-used and standardized survey of participant responses to 36 questions that measures health-related quality of life. Each question has answers that are given a correlating score from 0 to 100, with a high score representing a more favorable health state. Through the combination of specific questions and averaging the scores, there are 8 scales (physical functioning, role limitations due to physical health, role limitations due to emotional problems, vitality, mental health, social functioning, bodily pain, and general health) that are reported with scores from 0 to 100, with a high score representing a more favorable health state. These can also be averaged into a physical component summary score and mental component summary score that is again from 0 to 100, with a high score representing a more favorable health state.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>PTEN Gene Mutation</condition>
  <condition>PTEN Hamartoma Tumor Syndrome</condition>
  <condition>PTEN Hamartoma Syndrome</condition>
  <condition>Cowden Syndrome</condition>
  <condition>Bannayan Syndrome</condition>
  <condition>Bannayan Zonana Syndrome</condition>
  <condition>Polyposis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There will be a clinic visit and colonoscopy at study entrance with standard of care sampling and assessment of polyps, including resection of concerning polyps. The investigators will also collect data on well-being via the SF-36 health survey (a validated questionnaire to help monitor this aspect given anecdotal patient-level reports of improvement while on therapy).
Study subjects will then begin sirolimus 2 mg by mouth daily for 1 year.
Laboratories will be checked at 4 days after initiation, at 2 weeks after initiation, then every 4 weeks for 3 months, then every 3 months to complete the year of therapy
Participants will have a clinic visit at 3, 6 and 9 months and include well-being assessment with the SF-36 health survey.
Participants will have a clinic visit with well-being assessment and perform colonoscopy at study closure at 12 months. The investigators will perform standard of care sampling and assessment of polyps, including resection of concerning polyps.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Use of sirolimus 2 mg by mouth daily for 1 year</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cowden syndrome or other PTEN hamartoma tumor syndrome spectrum disorder

          -  Confirmed pathogenic or likely pathogenic PTEN germline mutation on genetic testing

          -  Previous colonoscopy with a burden of colon polyps that are too numerous to clear
             endoscopically (this is usually when polyp burden is estimated to be over 50 colon
             polyps)

          -  Age 18 or greater

          -  Capacity to consent to study

        Exclusion Criteria:

          -  Pregnancy or plans for pregnancy while on treatment or within 3 months of stopping
             treatment (for both women and men)

          -  Chronic kidney disease

          -  Chronic renal disease

          -  History of colon cancer or colon adenoma with high grade dysplasia

          -  History of colectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter P Stanich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter P Stanich, MD</last_name>
    <phone>(614) 293-6255</phone>
    <email>peter.stanich@osumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Casey McClurkin</last_name>
    <phone>(614) 688-9575</phone>
    <email>casey.mcclurkin@osumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter P Stanich, MD</last_name>
      <phone>614-293-6255</phone>
      <email>peter.stanich@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Casey McClurkin</last_name>
      <phone>(614) 688-9575</phone>
      <email>casey.mcclurkin@osumc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Stanich PP, Pilarski R, Rock J, Frankel WL, El-Dika S, Meyer MM. Colonic manifestations of PTEN hamartoma tumor syndrome: case series and systematic review. World J Gastroenterol. 2014 Feb 21;20(7):1833-8. doi: 10.3748/wjg.v20.i7.1833. Review.</citation>
    <PMID>24587660</PMID>
  </reference>
  <reference>
    <citation>Stanich PP, Owens VL, Sweetser S, Khambatta S, Smyrk TC, Richardson RL, Goetz MP, Patnaik MM. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc. 2011 Jun;86(6):489-92. doi: 10.4065/mcp.2010.0816.</citation>
    <PMID>21628613</PMID>
  </reference>
  <reference>
    <citation>Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010 Dec;139(6):1927-33. doi: 10.1053/j.gastro.2010.06.061. Epub 2010 Jun 27.</citation>
    <PMID>20600018</PMID>
  </reference>
  <reference>
    <citation>Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, Hornyak TJ, Wank S, Hewitt SM, Morrow B, Memmott RM, Rajan A, Dennis PA. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN. Oncologist. 2019 Dec;24(12):1510-e1265. doi: 10.1634/theoncologist.2019-0514. Epub 2019 Jul 26.</citation>
    <PMID>31350329</PMID>
  </reference>
  <reference>
    <citation>Lynch PM, Morris JS, Wen S, Advani SM, Ross W, Chang GJ, Rodriguez-Bigas M, Raju GS, Ricciardiello L, Iwama T, Rossi BM, Pellise M, Stoffel E, Wise PE, Bertario L, Saunders B, Burt R, Belluzzi A, Ahnen D, Matsubara N, BÃ¼low S, Jespersen N, Clark SK, Erdman SH, Markowitz AJ, Bernstein I, De Haas N, Syngal S, Moeslein G. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc. 2016 Jul;84(1):115-125.e4. doi: 10.1016/j.gie.2015.12.029. Epub 2016 Jan 6.</citation>
    <PMID>26769407</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Peter Stanich</investigator_full_name>
    <investigator_title>Associate Professor, Division of Gastroenterology, Hepatology &amp; Nutrition</investigator_title>
  </responsible_party>
  <keyword>PTEN</keyword>
  <keyword>Cowden syndrome</keyword>
  <keyword>PHTS</keyword>
  <keyword>Colon polyposis</keyword>
  <keyword>sirolimus</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>mTOR inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT04094675/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

